Substance use disorders (SUDs) are a major public health concern, with opioid use disorder (OUD) and alcohol use disorder ...

For patients with ischemic stroke, sodium-glucose cotransporter-2 inhibitors (SGLT-2is) and glucagon-like peptide-1 receptor ...

Unplanned pregnancies are still being reported among people using GLP-1 drugs, but now fertility specialists are ...

Recent studies have shown that pharmacological treatment with GLP-1-RA and dual GLP-1/glucose-dependent insulinotropic ...

GLP-1RA drugs and SGLT2 inhibitors were associated with a lower risk for nonalcoholic fatty liver disease among individuals with type 2 diabetes.

Recently the U.S. Food and Drug Administration (FDA) issued updated safety warnings for all glucagon-like peptide 1 receptor ...

Metsera is riding the wave of continued enthusiasm for GLP-1 drugs and its own early-stage data to bring in ... There is also ...

Glucagon-like peptide-1 receptor agonists, or GLP-1RAs, are medications that mimic a natural gut hormone, GLP-1, which helps ...

The GLP-1 RA cohort had significantly lower odds of ... with a diagnosis of type 2 diabetes (subsequently prescribed antidiabetic medications) but with no prior CRC diagnosis identified from ...

For patients with nephrolithiasis, sodium-glucose cotransporter-2 (SGLT-2) inhibitor use is associated with a reducti ...

“Our study provides one of the first national estimates of the decline in utilization of bariatric metabolic surgery among privately insured patients corresponding to the rising use of blockbuster GLP ...